Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cardiomyopathy Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Gamma Catenin/JUP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Gamma Catenin (JUP) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for PPI screening. |
View JUP Products |
| Gene Delivery | Gamma Catenin (JUP) Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and EMT modeling. |
View JUP Products |
| Benchmark Ab | Anti-Gamma Catenin (JUP) Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View JUP Products |
| Validator | Gamma Catenin (JUP) siRNA Set Target-specific knockdown verification in tumor cell migration assays. |
View JUP Products |
| Related Target A | Beta Catenin (CTNNB1) Homologous structural/signaling partner; essential for selectivity counter-screening. |
View CTNNB1 Products |
| Related Target B | E-Cadherin (CDH1) Primary adherens junction binding partner; crucial for cell adhesion disruption assays. |
View CDH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against Beta Catenin | High-purity human recombinant JUP and CTNNB1 proteins verified by mass spectrometry for parallel screening. |
| Stable Cell Line Construction for EMT | High-titer, sequence-verified Lentiviral particles ready for robust integration into epithelial tumor lines. |
| Lack of Controls | Highly specific recombinant monoclonal antibodies validated as positive controls for immunoprecipitation (IP). |
| False Positives in Knockdown | Multi-sequence pooled siRNA sets ensuring efficient gene silencing with minimal off-target risks. |
Live Gamma Catenin/JUP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Gamma Catenin (Junction Plakoglobin, JUP) is emerging as a critical frontier in oncology and cardiovascular medicine. In oncology, the focus has shifted from simple tumor suppression profiling to the active disruption of Circulating Tumor Cell (CTC) clusters. JUP is a master regulator of CTC cluster cohesion; knocking down or pharmacologically inhibiting JUP disrupts these clusters, drastically reducing metastatic potential. Concurrently, in cardiovascular pathology, JUP mutations remain central to the study of arrhythmogenic right ventricular cardiomyopathy (ARVC), driving demand for stable expression models to screen for stabilizing small molecules.
As drug discovery transitions from phenotypic screens to target-directed pipelines, the next wave of R&D relies heavily on dissecting JUP's dual role: its structural function at desmosomes/adherens junctions and its transcriptional signaling function in the nucleus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Spin-offs, Biotech | Metastatic Breast Cancer, Prostate Cancer | Protein-Protein Interaction (PPI) assays (Need high-purity recombinant JUP & CDH1) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Solid Tumors (Metastasis Prevention) | In vitro validation (Need validated siRNA knockdown & qPCR controls) |
| Gene Therapy / Overexpression | Cardiovascular Research Institutes | Arrhythmogenic Cardiomyopathy (ARVC) | Rescue assays (Need high-titer Lentivirus for stable cardiac cell lines) |